Merijn Joling1,2,3,4, Chris Vriend5,3,4,6, Odile A van den Heuvel3,4,6, Pieter G H M Raijmakers7, Paul A Jones8, Henk W Berendse5,3, Jan Booij2,3. 1. Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands me.joling@vumc.nl. 2. Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands. 3. Amsterdam Neuroscience, Amsterdam, The Netherlands. 4. Department of Anatomy and Neurosciences, VU University Medical Center, Amsterdam, The Netherlands. 5. Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands. 6. Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands. 7. Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands; and. 8. GE Healthcare, The Grove Centre, Amersham, United Kingdom.
Abstract
123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (123I-FP-CIT) SPECT can visualize and quantify striatal dopamine transporter (DAT) binding in vivo. In addition, 123I-FP-CIT has modest affinity for the serotonin transporter (SERT), predominantly represented in extrastriatal binding. On the basis of previous imaging studies that have suggested more pronounced degeneration of other monoaminergic systems in multiple-system atrophy (MSA) and progressive supranuclear palsy (PSP) than in Parkinson disease (PD), we hypothesized that, in addition to striatal DAT binding, there would be differences in extrastriatal 123I-FP-CIT SPECT binding to SERT between MSA, PSP, and PD. Methods: We included patients with parkinsonian type MSA (multiple-system atrophy with predominantly parkinsonism [MSA-P], n = 9), cerebellar type MSA (MSA-C, n = 7), PSP (n = 13), and PD (n = 30). 123I-FP-CIT binding was analyzed using region-of-interest (ROI)- as well as voxel-based methods in both the DAT-rich striatum (caudate nucleus and putamen) and the SERT-rich extrastriatal brain regions (thalamus, hypothalamus, and pons). For SERT analysis, patients on selective serotonin reuptake inhibitor were excluded (n = 48 remained). Results: In the ROI analyses, extrastriatal 123I-FP-CIT binding ratios in the hypothalamus were significantly lower in PSP than in MSA-C patients, and we observed significantly lower striatal 123I-FP-CIT binding ratios in the caudate nucleus of PSP patients than in that of both PD and MSA-C patients. In the posterior putamen, binding ratios were significantly lower in MSA-P, PSP, and PD than MSA-C patients. Striatal ROI outcomes were confirmed by the voxel-based analyses that additionally showed a significantly lower hypothalamic binding in PSP and MSA-P than PD. Conclusion: Striatal 123I-FP-CIT binding to DAT and hypothalamic 123I-FP-CIT binding to SERT are significantly lower in MSA-P and PSP than in PD and MSA-C patients and might therefore be of interest for differential diagnosis.
123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (123I-FP-CIT) SPECT can visualize and quantify striatal dopamine transporter (DAT) binding in vivo. In addition, 123I-FP-CIT has modest affinity for the serotonin transporter (SERT), predominantly represented in extrastriatal binding. On the basis of previous imaging studies that have suggested more pronounced degeneration of other monoaminergic systems in multiple-system atrophy (MSA) and progressive supranuclear palsy (PSP) than in Parkinson disease (PD), we hypothesized that, in addition to striatal DAT binding, there would be differences in extrastriatal 123I-FP-CIT SPECT binding to SERT between MSA, PSP, and PD. Methods: We included patients with parkinsonian type MSA (multiple-system atrophy with predominantly parkinsonism [MSA-P], n = 9), cerebellar type MSA (MSA-C, n = 7), PSP (n = 13), and PD (n = 30). 123I-FP-CIT binding was analyzed using region-of-interest (ROI)- as well as voxel-based methods in both the DAT-rich striatum (caudate nucleus and putamen) and the SERT-rich extrastriatal brain regions (thalamus, hypothalamus, and pons). For SERT analysis, patients on selective serotonin reuptake inhibitor were excluded (n = 48 remained). Results: In the ROI analyses, extrastriatal 123I-FP-CIT binding ratios in the hypothalamus were significantly lower in PSP than in MSA-C patients, and we observed significantly lower striatal 123I-FP-CIT binding ratios in the caudate nucleus of PSPpatients than in that of both PD and MSA-C patients. In the posterior putamen, binding ratios were significantly lower in MSA-P, PSP, and PD than MSA-C patients. Striatal ROI outcomes were confirmed by the voxel-based analyses that additionally showed a significantly lower hypothalamic binding in PSP and MSA-P than PD. Conclusion: Striatal 123I-FP-CIT binding to DAT and hypothalamic123I-FP-CIT binding to SERT are significantly lower in MSA-P and PSP than in PD and MSA-C patients and might therefore be of interest for differential diagnosis.
Authors: Elon D Wallert; Elsmarieke van de Giessen; Remco J J Knol; Martijn Beudel; Rob M A de Bie; Jan Booij Journal: J Nucl Med Date: 2022-06 Impact factor: 11.082
Authors: Dagmar N van Deursen; Odile A van den Heuvel; Jan Booij; Henk W Berendse; Chris Vriend Journal: J Neurol Date: 2020-03-12 Impact factor: 4.849
Authors: Merijn Joling; Chris Vriend; Pieter G H M Raijmakers; Jessica J van der Zande; Afina W Lemstra; Henk W Berendse; Jan Booij; Odile A van den Heuvel Journal: Neuroimage Clin Date: 2019-03-12 Impact factor: 4.881
Authors: Chris Vriend; Tim D van Balkom; Corné van Druningen; Martin Klein; Ysbrand D van der Werf; Henk W Berendse; Odile A van den Heuvel Journal: Neuroimage Clin Date: 2020-04-21 Impact factor: 4.881
Authors: Merijn Joling; Chris Vriend; Jessica J van der Zande; Afina W Lemstra; Odile A van den Heuvel; Jan Booij; Henk W Berendse Journal: Neuroimage Clin Date: 2018-04-06 Impact factor: 4.881